OBJECTIVE/BACKGROUND: Obesity is related to @entity2704 . @entity158 coping strategies (eg, @entity158 @entity16839 ) may provide insight into this relationship. In @entity1 with @entity2704 and @entity28 , we cross-sectionally assessed: (1) prevalence of clinical @entity16839 ; (2) characteristics of those with and without clinical @entity16839 ; and (3) associations of @entity16839 with @entity10 features. METHODS: Obese @entity1 migraineurs seeking weight loss treatment (n   =   105) recorded daily @entity2704 activity for 1 month via smartphone and completed the @entity158 ( @entity158 ). Clinical @entity16839 was defined as total @entity158 score >= 30. The six-item @entity10 Impact Test ( @entity19355 ), 12-item Allodynia Symptom Checklist (ASC-12), @entity10 Management Self-Efficacy Scale (HMSE), and assessments for @entity308 (Centers for Epidemiologic Studies Depression Scale) and @entity148 (seven-item Generalized @entity148 Scale) were also administered. Using @entity158 scores and body mass index (BMI) as predictors in linear regression, we modeled a series of @entity10 features (ie, @entity10 days, @entity19355 , etc) as outcomes. RESULTS: One quarter (25.7%; 95% confidence interval [CI]   =   17.2-34.1%) of @entity1 met criteria for clinical @entity16839 : they had higher BMI (37.9        7.5 vs 34.4        5.7   kg/m(2) , P   =   .035); longer @entity2704 attack duration (160.8        145.0 vs 97.5        75.2 hours/month, P   =   .038); higher @entity19355 scores (68.7        4.6 vs 64.5        3.9, P   <   .001); more @entity1931 (7.0        4.1 vs 4.5        3.5, P   <   .003), @entity308 (25.4        12.4 vs 13.3        9.2, P   <   .001), and @entity148 (11.0        5.2 vs 5.6        4.1, P   <   .001); and lower self-efficacy (80.1        25.6 vs 104.7        18.9, P   <   .001) compared with @entity1 without clinical @entity16839 . The odds of chronic @entity2704 were nearly fourfold greater in those with (n   =   8/29.6%) vs without (n   =   8/10.3%) clinical @entity16839 (odds ratio   =   3.68; 95%CI   =   1.22-11.10, P   =   .021). In all @entity1 , higher @entity158 scores were related to more @entity2704 days (b   =   0.331, P   =   .001), longer attack duration (b   =   0.390, P   <   .001), higher @entity19355 scores (b   =   0.425, P   <   .001), and lower HMSE scores (b   =   -0.437, P   <   .001). Higher BMI, but not higher @entity158 scores, was related to more frequent attacks (b   =   -0.203, P   =   .044). CONCLUSIONS: One quarter of @entity1 with @entity2704 and @entity28 reported clinical @entity16839 . These individuals had more frequent attacks/chronicity, longer attack duration, @entity158 sensitivity, greater @entity10 impact, and lower @entity10 management self-efficacy. In all @entity1 , @entity158 scores were related to several @entity2704 characteristics, above and beyond the effects of @entity28 . Prospective studies are needed to determine sequence and mechanisms of relationships between @entity16839 , @entity28 , and @entity2704 .

Clinical @entity158 Catastrophizing in XXXX With @entity28 .

@entity1 :: ('9606', 'Species') :: ['participants', 'women'] @entity308 :: ('MESH:D003866', 'Disease') :: ['depression'] @entity1931 :: ('MESH:D006930', 'Disease') :: ['allodynia'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity'] @entity2704 :: ('MESH:D008881', 'Disease') :: ['migraine'] @entity16839 :: ('MESH:D002388', 'Disease') :: ['catastrophizing'] @entity148 :: ('MESH:D001008', 'Disease') :: ['anxiety', 'Anxiety Disorder'] @entity158 :: ('MESH:D010146', 'Disease') :: ['PCS', 'higher pain', 'Maladaptive pain', 'pain', 'Pain Catastrophizing Scale'] @entity19355 :: ('MESH:D005077', 'Disease') :: ['HIT-6'] @entity10 :: ('MESH:D006261', 'Disease') :: ['Headache', 'headache']
@entity1 :: (9606,Species) :: ['Women']
